Dr. Eric Wallace
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 55
Licensed in Alabama since 2007, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Alabama School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
AL license 28356 (first issued 2007; active) · FL license TPME2760 · MS license 29599 · TN license 46045
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 55
- Services billed
- 289
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Home dialysis services per month (20 years or older) | 147 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 21 payments worth $42,751 in total to this clinician.
| Genzyme Corporation | $32,476 |
|---|---|
| Chiesi USA, Inc. | $9,948 |
| Sanofi US Services Inc. | $139 |
| Novo Nordisk Inc | $125 |
| Vantive US Healthcare LLC | $64.44 |
| Consulting Fee | $18,800 |
|---|---|
| Travel and Lodging | $18,153 |
| Compensation for services other than consulting (speaking, faculty) | $4,800 |
| Food and Beverage | $998 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 20, 2025 | Consulting Fee | $10,672 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging travel to Amsterdam, Netherlands · in-kind | $9,864 |
| Chiesi USA, Inc. Dec 1, 2025 | Travel and Lodging travel to LONDON, Great Britain (UK) | $7,403 |
| Genzyme Corporation Jun 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,800 |
| Genzyme Corporation Sep 15, 2025 | Consulting Fee | $3,200 |
| Genzyme Corporation May 3, 2025 | Consulting Fee | $2,668 |
| Chiesi USA, Inc. Jan 2, 2025 | Consulting Fee ELFABRIO · ERT FOR FABRY DISEASE | $2,260 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging travel to Amsterdam, Netherlands · in-kind | $510 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging travel to Amsterdam, Netherlands | $370 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging travel to Amsterdam, Netherlands · in-kind | $6.21 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $266,806 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
Genzyme Corporation · Active, not recruiting · NCT05280548 - Fabry Disease Registry & Pregnancy Sub-registry
Sanofi US Services Inc. · Recruiting · NCT00196742 - A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
Genzyme Corporation · Active, not recruiting · NCT05206773
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.